References
- http://en.wikipedia.org/wiki/Patient_information_leaflet
- http://www.ema.europa.eu/ema/index.jsp?curl = pages/regulation/general/general_content_000199.jsp&mid = WC0b01 ac0580022bb3
- Herber OR, Gies V, Schwappach D, Thürmann P, Wilm S. Patient information leaflets: informing or frightening? A focus group study exploring patients’ emotional reactions and subsequent behavior towards package leaflets of commonly prescribed medications in family practices. BMC Fam Pract 2014;15:163
- Liu F, Abdul-Hussain S, Mahboob S, Rai V, Kostrzewski A. How useful are medication patient information leaflets to older adults? A content, readability and layout analysis. Int J Clin Pharm 2014;36:827–34
- Ziegler A, Hadlak A, Mehlbeer S, König IR. Comprehension of the description of side effects in drug information leaflets: a survey of doctors, pharmacists and lawyers. Dtsch Arztebl Int 2013;110:669–73
- Mira JJ, Lorenzo S, Pérez-Jover V, Navarro I, Martín de Rosales AM, Lara C. Assessment of the quality of medication information for patients in Spain. Expert Opin Drug Saf 2013; 12:9–18
- Burgers C, Beukeboom CJ, Sparks L, Diepeveen V. How (not) to inform patients about drug use: use and effects of negations in Dutch patient information leaflets. Pharmacoepidemiol Drug Saf 2014 Jul 15. Epub ahead of print
- Watkins ES. ‘Doctor, are you trying to kill me?‘: ambivalence about the patient package insert for estrogen. Bull Hist Med 2002;76:84–104
- Manson JE, Goldstein SR, Kagan R, et al. Why the product labeling for low-dose vaginal estrogen should be changed. Menopause 2014;21:911–6
- http://www.novonordisk-us.com/Images/PDF/Vagifem_Nov_25_2009.pdf
- Schwappach DL, Mülders V, Simic D, Wilm S, Thürmann PA. Is less more? Patients’ preferences for drug information leaflets. Pharmacoepidemiol Drug Saf 2011;20:987–95
- Fenton A, Panay N. Communication – do we have a problem? Climacteric 2008;11:265–6